Material Event (Form 8-K)

As previously reported, on June 20, 2024, The Oncology Institute, Inc. (the "Company") received a written notification from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") that the closing bid price of the Company's common stock had been below $1.00 per share for the previous 30 consecutive business days, and that, as a result, the Company was not in compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the "Rule"). The Company was provided 180 calendar days, until December 17, 2024, to regain compliance. However, in a letter dated December 19, 2024, Nasdaq notified the Company that the staff of the Nasdaq Listing Qualifications Department (the "Listing Qualifications Staff") determined that the Company was eligible for an additional 180 calendar day period, or until June 16, 2025, to regain compliance.

On April 9, 2025, the Company received written notice from the Listing Qualifications Staff notifying the Company that, for the last 12 consecutive business days, from March 24, 2025 through April 8, 2025, the closing bid price of the Company's common stock was $1.00 per share or greater. Accordingly, the written notice stated that the Company has regained compliance with the minimum bid price listing requirement set forth under the Rule.